English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/8834
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorMooij, Petra-
dc.contributor.authorBalla-Jhagjhoorsingh, Sunita S.-
dc.contributor.authorKoopman, Gerrit-
dc.contributor.authorBeenhakker, Niels-
dc.contributor.authorVan Haaften, Patricia-
dc.contributor.authorBaak, Ilona-
dc.contributor.authorNieuwenhuis, Ivonne G.-
dc.contributor.authorKondova, Ivanela-
dc.contributor.authorWagner, Ralf-
dc.contributor.authorWolf, Hans-
dc.contributor.authorGómez, Carmen E.-
dc.contributor.authorNájera García, José Luis-
dc.contributor.authorJiménez, Victoria-
dc.contributor.authorEsteban, Mariano-
dc.contributor.authorHeeney, Jonathan L.-
dc.identifier.citationJournal of Virology 82(6): 2975-2988 (2008)en_US
dc.description14 pages, 8 figures.-- PMID: 18184713 [PubMed].-- Supplementary material available: Table S1: DNA sequence of MVA-89.6p-SIVgpn in the TK viral locus.-- Printed version published on Mar 2008.en_US
dc.description.abstractPoxvirus vectors have proven to be highly effective for boosting immune responses in diverse vaccine settings. Recent reports reveal marked differences in the gene expression of human dendritic cells infected with two leading poxvirus-based human immunodeficiency virus (HIV) vaccine candidates, New York vaccinia virus (NYVAC) and modified vaccinia virus Ankara (MVA). To understand how complex genomic changes in these two vaccine vectors translate into antigen-specific systemic immune responses, we undertook a head-to-head vaccine immunogenicity and efficacy study in the pathogenic HIV type 1 (HIV-1) model of AIDS in Indian rhesus macaques. Differences in the immune responses in outbred animals were not distinguished by enzyme-linked immunospot assays, but differences were distinguished by multiparameter fluorescence-activated cell sorter analysis, revealing a difference between the number of animals with both CD4+ and CD8+ T-cell responses to vaccine inserts (MVA) and those that elicit a dominant CD4+ T-cell response (NYVAC). Remarkably, vector-induced differences in CD4+/CD8+ T-cell immune responses persisted for more than a year after challenge and even accompanied antigenic modulation throughout the control of chronic infection. Importantly, strong preexposure HIV-1/simian immunodeficiency virus-specific CD4+ T-cell responses did not prove deleterious with respect to accelerated disease progression. In contrast, in this setting, animals with strong vaccine-induced polyfunctional CD4+ T-cell responses showed efficacies similar to those with stronger CD8+ T-cell responses.en_US
dc.description.sponsorshipThis study was supported by funding from the EuroVacc (European Vaccine Effort Against HIV/AIDS) project QLK2-CT-1999-1321.en_US
dc.format.extent1331362 bytes-
dc.publisherAmerican Society for Microbiologyen_US
dc.subjectImmune response enhancementen_US
dc.subjectPoxvirus vectorsen_US
dc.subjectHuman immunodeficiency virus (HIV)en_US
dc.subjectVaccine candidatesen_US
dc.subjectNew York vaccinia virus (NYVAC)en_US
dc.subjectModified vaccinia virus Ankara (MVA)en_US
dc.subjectCD4+/CD8+ T-cell immune responseen_US
dc.subjectIndian rhesus macaquesen_US
dc.titleDifferential CD4+ versus CD8+ T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primatesen_US
dc.description.peerreviewedPeer revieweden_US
Appears in Collections:(CNB) Artículos
Files in This Item:
There are no files associated with this item.
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.